Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07075718 · ClinicalTrials.gov registry record · Phase 2
Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
A Phase 2 study of Glaucoma, sponsored by Glaukos Corporation.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 610
- Enrollment target
- 3
- Study locations
NCT07075718 is a Phase 2 study of Glaucoma that is actively recruiting participants, run by Glaukos Corporation. The registered enrollment target is 610 participants, below the 904-participant average among 92 other Glaucoma trials with a reported enrollment target (33% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT07075718, a Phase 2 study of Glaucoma, is actively recruiting participants, sponsored by Glaukos Corporation.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 610 participants
- Enrollment target
- 3
- Study locations
Study Summary
Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
Conditions Studied
Interventions
- PROCEDURE Sham Procedure
- DRUG Gen 2 Travoprost Intracameral Implant
- DRUG Timolol eye drops 0.5%
- OTHER Placebo eye drops
Study Locations (3)
Colorado
- Glaukos Investigative Site - Grand Junction
Oklahoma
- Glaukos Investigative Site - Oklahoma City
Texas
- Glaukos Clinical Site - El Paso
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 610 participants |
| Start Date | 2025-06-12 |
| Est. Completion | 2032-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07075718
The ClinicalTrials.gov registry entry for NCT07075718 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 610 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 904-participant average among 92 other Glaucoma trials with a reported enrollment target (33% lower). The listed sponsor is Glaukos Corporation, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glaucoma appearing as the primary indexed condition, and to 4 interventions - of which Sham Procedure is the first listed.
NCT07075718 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Colorado, Oklahoma, Texas.
Frequently Asked Questions
What is clinical trial NCT07075718 about?
NCT07075718 is a clinical study titled "Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant". Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
What is the current status of trial NCT07075718?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 610 participants. The study started on 2025-06-12. Estimated completion is 2032-03.
What conditions does trial NCT07075718 study?
This clinical trial studies the following conditions: Glaucoma.
What interventions are being tested in trial NCT07075718?
The interventions under investigation include: Sham Procedure (PROCEDURE), Gen 2 Travoprost Intracameral Implant (DRUG), Timolol eye drops 0.5% (DRUG), Placebo eye drops (OTHER).
Who is sponsoring clinical trial NCT07075718?
This trial is sponsored by Glaukos Corporation, which has 33 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07075718 being conducted?
This trial has 3 study locations across Colorado, Oklahoma, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glaucoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension
RECRUITING · Phase 2
-
Study of NT-501 Encapsulated Cell Therapy for Glaucoma Neuroprotection and Vision Restoration
ACTIVE NOT RECRUITING · Phase 2
-
Dual Intravitreal Implantation of NT-501 Encapsulated Cell Therapy for Glaucoma
ACTIVE NOT RECRUITING · Phase 2
-
Circadian Rhythms of Aqueous Humor Dynamics in Humans
COMPLETED · Phase 2
-
Multiple Dose-escalation Study of AMA0076 in Patients With Ocular Hypertension or Primary Open-angle Glaucoma
COMPLETED · Phase 2
-
A Safety and Efficacy Study of Fixed-Combination Bimatoprost and Brimonidine in Chronic Glaucoma or Ocular Hypertension
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.